CrossCountry Consulting Recognized on the Inc. 5000 for the Eighth Consecutive Year
Leading business advisory firm among fastest-growing private U.S. companies with three-year revenue growth of 110%…
Month: August 2023
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
Orlando, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC…
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
Orlando, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC…
Elevar Therapeutics Names Dr. Chris Galloway Vice President of Clinical Development
FORT LEE, N.J., Aug. 15, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary…
Elevar Therapeutics Names Dr. Chris Galloway Vice President of Clinical Development
FORT LEE, N.J., Aug. 15, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary…
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023
LONDON and NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO),…
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023
LONDON and NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO),…
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients…
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients…
Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on New ‘Dendranib’ Nanomedicine Candidate at the 16th International Society of Neuroimmunology Congress (ISNI)
Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor…
Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on New ‘Dendranib’ Nanomedicine Candidate at the 16th International Society of Neuroimmunology Congress (ISNI)
Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor…
Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023
COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced…
Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023
COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced…
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack®…
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack®…
Aruna Bio Announces Oral Presentation on Treatment Opportunities of Lead Program, AB126 at the Exosome Based Therapeutic Development Summit and Applications of Exosomes BioProcess International Conference & Exhibition
– AB126 is an unmodified exosome derived from neural stem cells with the innate ability…
Aruna Bio Announces Oral Presentation on Treatment Opportunities of Lead Program, AB126 at the Exosome Based Therapeutic Development Summit and Applications of Exosomes BioProcess International Conference & Exhibition
– AB126 is an unmodified exosome derived from neural stem cells with the innate ability…
IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…
IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…
Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program
-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in…